Search

Objective: Peritoneal dialysis is a widely used renal replacement therapy for end-stage renal disease (ESRD). This study aims to evaluate the duration of use and complications associated with peritoneal dialysis catheters (PDC) placed using an open surgical method in a singlecenter experience. Materials and Methods: This study included 127 ESRD patients who underwent PDC placement between 2018 and 2023. We analyzed the patients' clinical and demographic data, the reasons for transitioning to hemodialysis, and the complications leading to this transition. Patients with a body mass index (BMI) of 30 or higher were considered obese, and the impact of this condition on complications was specifically investigated. The PDC placement using the open surgical method was performed by the same surgical team. Results: Of the 127 patients who had PDCs placed in the last five years, approximately 55.1% experienced various complications, leading to a transition to hemodialysis in 31 patients. Reasons for switching included catheter-related problems (35.4%), peritonitis (25.8%), ultrafiltration failure (19.3%), dialysis inadequacy (6.4%), and hernia (3.2%). No significant change in the overall risk of complications was observed in patients with a BMI of 30 or higher; however, a significant increase in the risk of peritonitis was noted in these patients. Conclusion: The open surgical method is a preferred technique for PDC placement due to its ease of application and low complication rates. Notably, in patients with a BMI of 30 or higher, an increase in infection-related complications, such as peritonitis, was observed. Therefore, greater attention should be devoted to managing infection-related complications in the use of PDCs among obese patients. [ABSTRACT FROM AUTHOR]

Aim: This study aimed to determine the effects of adjuvant therapy on body mass index (BMI) and body fat (BF) measurements in women with early-stage breast cancer (ESBC). Material and Methods: We prospectively evaluated BMI and BF measurements including trunk fat mass kilograms (kg), trunk fat mass (%) and total body fat (%) on a bioelectric impedance analyzer in 29 women with stages I-III breast cancer. All of the patients received anthracycline-based adjuvant chemotherapy (ACT). Six patients were hormone receptor (HR)-negative. Twenty-three patients were HR-positive and received adjuvant endocrine therapy (AET) following ACT. Eleven HR-positive postmenopausal patients were treated with an aromatase inhibitor (AI), and the remaining twelve HR-positive premenopausal patients were treated with tamoxifen (TMX). A total of 3 measurements were performed in the beginning of chemotherapy, at 6th, and 12th months. Results: Although the BMI was significantly increased, there was no significant change in the BF during chemotherapy in patients receiving only ACT. Both BMI and BF measurements were significantly increased in premenopausal patients receiving TMX after ACT. However, no significant change was observed in BMI and BF measurements in postmenopausal patients receiving AI after ACT. Conclusions: ACT increased both BMI and BF measurements in patients with HR-positive premenopausal ESBC. Treatment with TMX or AI after ACT did not enhance the changes due to chemotherapy on body composition. Therefore, especially patients with HR-positive premenopausal ESBC should be careful not to gain weight during ACT. [ABSTRACT FROM AUTHOR]